LGALS3 and prostate carcinoma: In addition, low doses of docetaxel inhibited the expression of the Galectin-3 in prostate cancer cells as well as in clinical samples of patients with metastatic cancer and CRPC, controlling tumor recurrence by increasing proliferation and infiltration of CD8+ cytotoxic T (49).